Laboratory for Neglected Disease Drug Discovery

Therapeutic Approaches: Small Molecules

Therapeutic Areas of Expertise: Infectious Diseases

Center/Program Highlights: Neglected diseases are those which do not attract sizable research investment in the private sector, since these diseases affect the poorest parts of the world. Since there will be little-to-no potential to recoup the research and development costs (let alone make a profit), biopharmaceutical companies do not typically marshal research programs of great significance against these diseases. Therefore, this represents a major opportunity for public sector, not-for-profit entities (such as academic institutions) to play a major role in developing new therapies for neglected diseases.

The main thrust of our program is to identify biological targets in pathogenic parasites that are homologous to biological targets in humans that have been pursued for drug discovery efforts in the past. We then repurpose these historical drug discovery efforts (compounds, structural information, general knowledge) for discovering new drugs against the parasite targets. Each of the four programs below have been initiated, recognizing the presence and importance of these targets in trypanosomes, and noting the deep medicinal chemistry knowledge that is available to guide development of new inhibitors for each of these trypanosomal targets.

Sources of Funding: Federal/State, Industry Partnerships, University


Institutional Affiliation(s):

Hurtig 102
360 Huntington Avenue
Massachusetts, 02115
United States

Center/Program Start Date: 2009

Number of Employees: 12